Physician profile
Junyue Qu
NPI 1215345558
$3,197.46
in general payments reported to CMS, 2019-2025
25 companies · $783 in 2025
The $783 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $106 · 2021: $307 · 2022: $410 · 2023: $592 · 2024: $717 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.16 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $556.61 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $480.07 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $440.99 | 2022-2025 | Xiidra, Vyzulta, Lotemax Sm |
| Alcon Vision LLC | $348.82 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Novartis Pharmaceuticals Corporation | $194.14 | 2021-2023 | |
| Abbvie INC. | $142.03 | 2023-2025 | |
| Coopervision INC. | $139.68 | 2019-2024 | Paragon Crt, Myday Contact Lens |
| Kala Pharmaceuticals, INC. | $134.88 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $118.59 | 2019-2023 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $95.01 | 2019-2021 | |
| Allergan, INC. | $94.92 | 2019-2021 | |
| Oyster Point Pharma, INC. | $79.09 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $52.89 | 2025 | Vevye |
| Sight Sciences, INC. | $51.37 | 2025 | Tearcare System |
| Dompe US, INC. | $48.84 | 2021-2025 | Oxervate |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $36.80 | 2025 | Iyuzeh |
| Regeneron Healthcare Solutions, INC. | $35.39 | 2023 | Eylea |
| Biotissue Holdings INC. | $28.32 | 2021-2022 | |
| Lkc Technologies, INC. | $26.60 | 2025 | |
| Amgen INC. | $17.53 | 2024 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $15.96 | 2023 | Acuvue |
| Eyevance Pharmaceuticals LLC | $14.97 | 2022 | |
| Novo Nordisk INC | $14.97 | 2020 | |
| Shire North American Group INC | $14.72 | 2019 | |
| Eyepoint US, INC. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junyue Qu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.